Clinical Trial

Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD

Study acronym: DELPHI
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
interventional trial for off label use of high dose atorvastatin 80 mg in intermediate AMD patients and correlate recovery response measured by dark adaptation recovery time with drusen volume reduction measured by SD-OCT
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-01-30; most recent amendment 2026-01-22.
Status change: Not Yet Recruiting → Recruiting 2021-10-07
Trial Details
NCT Number NCT04735263
Lead Sponsor Massachusetts Eye and Ear Infirmary
Conditions Age-related Macular Degeneration
Enrollment 21 participants
Start Date 2021-02-04
Primary Completion 2027-04-01 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-26